Stockreport

New Publication Summarizes Phase 1 Studies of CK-2127107 Showing Tolerability and Amplification of Skeletal Muscle Response to Nerve Activation

Cytokinetics, Incorporated  (CYTK) 
Last cytokinetics, incorporated earnings: 3/3 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.cytokinetics.com/investor-overview
PDF Next Generation Fast Skeletal Muscle Activator Appears Promising Compared to Tirasemtiv in Studies of Healthy Volunteers SOUTH SAN FRANCISCO, Calif., Nov. 30, 2017 (G [Read more]